The estimated cumulative risk (i.e. penetrance) of prostate cancer to age 55 years in Caucasian men due to carrying a disease-associated BRCA2 mutation is about 1.1%, and the population attributable risk of prostate cancer in this same group is 0.7%. Here, BRCA2 is linked to prostate carcinoma.